Theravance Biopharma, Inc. (TBPH) is a publicly traded Healthcare sector company. As of May 21, 2026, TBPH trades at $16.54 with a market cap of $838.25M and a P/E ratio of 7.31. TBPH moved +1.72% today. Year to date, TBPH is -10.15%; over the trailing twelve months it is +75.13%. Its 52-week range spans $7.88 to $21.03. Analyst consensus is buy with an average price target of $16.61. Rallies surfaces TBPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Theravance Biopharma, Inc. (TBPH) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. TBPH moved +1.72% today. Analyst consensus is buy.
| Metric | Value |
|---|---|
| Price | $16.54 |
| Market Cap | $838.25M |
| P/E Ratio | 7.31 |
| EPS | $2.26 |
| Dividend Yield | 0.00% |
| 52-Week High | $21.03 |
| 52-Week Low | $7.88 |
| Volume | 385.08K |
| Avg Volume | 0 |
| Revenue (TTM) | $109.78M |
| Net Income | $114.54M |
| Gross Margin | 0.00% |
6 analysts cover TBPH: 0 strong buy, 3 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $16.61.